These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 12679711)
1. In vivo cell-mediated immunity in subjects with undetectable viral load on protease inhibitor-based versus non-protease inhibitor-based highly active antiretroviral therapy. Ananworanich J; Nuesch R; Teeratakulpisarn S; Srasuebkul P; Chuenyam T; Siangphoe U; Ungsedhaphand C; Phanuphak P; Ruxrungtham K J Acquir Immune Defic Syndr; 2003 Apr; 32(5):570-2. PubMed ID: 12679711 [No Abstract] [Full Text] [Related]
2. [Highly active initial therapy without resistance development. Even after 6 years still effective HIV therapy]. MMW Fortschr Med; 2005 Apr; 147 Spec No 1():54-5. PubMed ID: 16385876 [No Abstract] [Full Text] [Related]
6. Patterns of response (CD4 cell count and viral load) at 6 months in HIV-infected patients on highly active antiretroviral therapy. Barreiro PM; Dona MC; Castilla J; Soriano V AIDS; 1999 Mar; 13(4):525-6. PubMed ID: 10197384 [No Abstract] [Full Text] [Related]
7. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. Cohen CJ; Hunt S; Sension M; Farthing C; Conant M; Jacobson S; Nadler J; Verbiest W; Hertogs K; Ames M; Rinehart AR; Graham NM; AIDS; 2002 Mar; 16(4):579-88. PubMed ID: 11873001 [TBL] [Abstract][Full Text] [Related]
8. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience. Gray CM; Schapiro JM; Winters MA; Merigan TC AIDS Res Hum Retroviruses; 1998 May; 14(7):561-9. PubMed ID: 9591710 [TBL] [Abstract][Full Text] [Related]
9. Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy. Marra CM; Lockhart D; Zunt JR; Perrin M; Coombs RW; Collier AC Neurology; 2003 Apr; 60(8):1388-90. PubMed ID: 12707454 [TBL] [Abstract][Full Text] [Related]
10. Genotypic analysis of plasma HIV-1 RNA after influenza vaccination of patients with previously undetectable viral loads. Kolber MA; Gabr AH; De La Rosa A; Glock JA; Jayaweera D; Miller N; Dickinson GM AIDS; 2002 Mar; 16(4):537-42. PubMed ID: 11872996 [TBL] [Abstract][Full Text] [Related]
11. Vaccination and HIV-1 replication during highly active antiretroviral therapy. Kroon FP; Beersma MF; Kroes AC; Groeneveld PH; van Dissel JT AIDS; 1999 Jan; 13(1):135-6. PubMed ID: 10207556 [No Abstract] [Full Text] [Related]
12. Sustained CD4 responses after virological failure of protease inhibitor-containing therapy. Deeks SG; Grant RM Antivir Ther; 1999; 4 Suppl 3():7-11. PubMed ID: 16021865 [TBL] [Abstract][Full Text] [Related]
13. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial. Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E; Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227 [TBL] [Abstract][Full Text] [Related]
14. Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: a median follow-up of 64 weeks. Rey D; Schmitt MP; Partisani M; Hess-Kempf G; Krantz V; de Mautort E; Bernard-Henry C; Priester M; Cheneau C; Lang JM J Acquir Immune Defic Syndr; 2001 Aug; 27(5):459-62. PubMed ID: 11511822 [TBL] [Abstract][Full Text] [Related]
15. Viral load and CD4 cell response to protease inhibitor-containing regimens in subtype B versus non-B treatment-naive HIV-1 patients. De Wit S; Boulmé R; Poll B; Schmit JC; Clumeck N AIDS; 2004 Nov; 18(17):2330-1. PubMed ID: 15577548 [TBL] [Abstract][Full Text] [Related]